Janus Kinase Inhibitors against Other Biological Treatments in Alopecia Areata
نویسندگان
چکیده
منابع مشابه
Translational Positioning of Janus Kinase (JAK) Inhibitors in Alopecia Areata
Alopecia areata (AA) is an autoimmune disease due to T cell attack of observation made in a special patient is complemented with mechanisthe hair follicles and breakdown of their immune privilege resulting in transient non-scarring hair loss which may last from weeks to decades and which presents an enormous psychological burden. As so far no FDA approved successful treatments for AA are availa...
متن کاملCurrent Treatments for Alopecia Areata.
Selection of a therapy for a patient with alopecia areata (AA) is frequently based on the age of the patient, disease extent, perhaps disease duration, patient expectations, cost of therapy in terms of time commitment, and financial resources, as well as the results of screening laboratory studies that rule out the presence of other co-morbidities such as anemia, low iron stores, thyroid abnorm...
متن کاملCytokines and Other Mediators in Alopecia Areata
Alopecia areata, a disease of the hair follicles with multifactorial etiology and a strong component of autoimmune origin, has been extensively studied as far as the role of several cytokines is concerned. So far, IFN-gamma, interleukins, TNF-alpha, are cytokines that are well known to play a major role in the pathogenesis of the disease, while several studies have shown that many more pathways...
متن کاملThe new biologics in psoriasis: possible treatments for alopecia areata.
Therapeutics in alopecia areata (AA) have remained relatively unchanged for many years, with few treatments having more than moderate effects in severely affected patients. The advent of the new biologic medications in the dermatologic world, however, particularly in psoriasis treatment, introduces possibilities of treatment for many other immune-mediated diseases.
متن کاملAlopecia areata.
n engl j med 367;3 nejm.org july 19, 2012 279 methacin should be used in addition to pancre atic stents in highrisk patients. However, post hoc analysis of our trial suggests that indometha cin may obviate the need for prophylactic pan creatic stent placement (unpublished data), and we therefore agree with Baron et al. that com parative effectiveness studies of indomethacin and pancreatic ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Scandinavian Journal of Immunology
سال: 2016
ISSN: 0300-9475
DOI: 10.1111/sji.12423